Diagnostic Demands in Clinical and Experimental Oncology: Application of Substrates Labeled with Positron-Emitting Radionuclides

Conference paper


In recent years, new regimens for the treatment of a variety of malignant tumors have led to greatly increased disease-free survival rates. For example, the introduction of high-dose methotrexate (HDMTX) with citrovorum factor rescue by Jaffe (1) for osteogenic sarcoma was a major breakthrough in the treatment of that highly malignant bone tumor. Later, Jaffe et al. (2), Rosen et al. (3) and Sutow et al. (4) found that primary osteogenic sarcoma, and its systemic metastases, could be better controlled by using HDMTX in combination with other drugs such as doxorubicin (adriamycin) and cyclophosphamide (cytoxan). In 1976, Rosen and co-workers reported their results in a series of patients who were treated with HDMTX and adriamycin preoperatively in an attempt to control and shrink the primary tumor and to eradicate metastatic disease at an early point in the regimen. These patients were noted to have a better disease-free survival than patients treated with post-operative adjuvant chemotherapy (5). Recent regimens for osteogenic sarcoma and Ewing sarcoma have further increased the survival of patients with these diseases (6, 7, 8). Today, more than 80% of patients with osteogenic sarcoma can expect to survive 5 years following intensive chemotherapy (9), compared to less than 20% in 1970 (10).


Osteogenic Sarcoma Label Amino Acid Embryonal Rhabdomyosarcoma Primary Osteogenic Sarcoma Mesenchymal Chondrosarcoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jaffe N (1972) Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer 30; 1627–1631PubMedCrossRefGoogle Scholar
  2. 2.
    Jaffe N, Frei E, Traggis D, Cassady JR, Watts H, Fuller RM (1977) High dose methotrexate with citrovorum factor in osteogenic sarcoma–Progress Report Il. Cancer Treat Reports 61; 676–679Google Scholar
  3. 3.
    Rosen G, Tan C, Sanmaneechai A, Beattie EJ, Marcove R, Murphy ML (1975) The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma. Cancer 35; 622–630PubMedCrossRefGoogle Scholar
  4. 4.
    Sutow WW, Sullivan MP, Fembach DJ (1975) Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. Cancer 36; 1598–1602PubMedCrossRefGoogle Scholar
  5. 5.
    Rosen G, Murphy ML, Huvos AG, Guttieren M, Marcove RC (1976) Chemotherapy, en bloc resection and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 37; 1–1tPubMedCrossRefGoogle Scholar
  6. 6.
    Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos AG (1979) Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 43; 2163–2177PubMedCrossRefGoogle Scholar
  7. 7.
    Rosen G, Caparros B, Mosende C, McCormick B, Huvos AG, Marcove RC (1978) Curability of Ewing’s sarcoma and considerations for future therapeutic trials. Cancer 41; 888499Google Scholar
  8. 8.
    Rosen G (1978) Primary Ewing’s sarcoma: the multidisciplinary lesion. Intl Radiat Goal Biol Phys 4; 527–432Google Scholar
  9. 9.
    Rosen G, Nirenberg A, Juergen H, Caparros B, Huvos AG (1980) Response of primary osteogenic sarcoma to single agent therapy with high-dose methotrexate with citrovorum factor rescue. In: Nelson JD, Grassi C (eds) Current chemotherapy and infectious disease. Proceedings of the Eleventh International Congress of Chemotherapy and the Nineteenth Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC. American Society for MicrobiologyGoogle Scholar
  10. 10.
    Marcove RC, Mike V, Hajek JV, Levin AG, nutter RVP (1970) Gsteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases. J Bone Joint Surg [Am] 52; 411–423Google Scholar
  11. 11.
    Smith J, Heelan RT, Huvos AG, Caparrot B, Rosen G, Urmacher C, Caravelli JF (1982) Radiographic changes in primary osteogenic sarcoma following intensive chemotherapy. Radiological-pathological correlation in 63 patients. Radial 143; 355–360Google Scholar
  12. 12.
    Frankel RS, Jones AE, Cohen IA, Johnson KW, Johnston GS, Pomeroy TC (1974) Clinical correlations of Go-67 and skeletal whole-body radionuclide studies with radiography in Ewing’s sarcoma. Radial 110; 597 603Google Scholar
  13. 13.
    McKillop IH, Etcubanas E, Goris ML (1981) The indications for and limitations of bone scintigraphy in osteogenic sarcoma: a review of 55 patients. Cancer 48; 1133–1138PubMedCrossRefGoogle Scholar
  14. 14.
    Goldstein H, McNeil BJ, Zufall E, Treves S (1980) Is there still a place for bone scanning in Ewing’s sarcoma? I Nod Med 21; 10–12Google Scholar
  15. 15.
    Cohen MB, Spolter L, McDonald NS, Cassen B (1972) Enzymatic synthesis of N-13 L-glutamine. J Nucl Med 13; 422Google Scholar
  16. 16.
    Lembares N, Dinwoodie R, Gloria I, Harper P, Lathrop K (1972) A rapid enzymatic synthesis of 10-minute N-13-glutamate and its pancreatic localization. J Nucl Med 13; 786Google Scholar
  17. 17.
    Gelbard AS, Clarke LP, McDonald JM, Monahan WG, Tilbury RS, Kuo TYT, Laughlin JS (1975) Enzymatic synthesis and organ distribution studies with N13-labeled L-glutamine and L-glutamic acid. Radiol 116; 127–132Google Scholar
  18. 18.
    Laughlin JS, Weber DA, Kenny PJ, Corey KR, Greenberg E (1964) Total body scanning. BrJ Radiol 37; 287–296CrossRefGoogle Scholar
  19. 19.
    Gelbard AS, Christie TR, Clarke LP, Laughlin JS (1977) Imaging of spontaneous cane tumors with ammonia and L-glutamine labeled with N-13. J Nucl Med 18; 718–723PubMedGoogle Scholar
  20. 20.
    McDonald JM, Gelbard AS, Clarke LP, Christie TR, Laughlin JS (1976) Imaging of tumors involving bone with N-13-glutamic acid. Radiol 120; 623 626Google Scholar
  21. 21.
    Rosen G, Gelbard AS, Benua RS, Laughlin JS, Reiman RE, McDonald JM (1979) N-13 glutamate scanning to detect the early response of bone tumors to chemotherapy. Proc Am Assoc Cancer Res, March 1979; 189Google Scholar
  22. 22.
    Gelbard AS, Benua RS, Laughlin JS, Rosen G, Reiman RE, McDonald JM (1979) Quantitative scanning of osteogenic sarcoma with nitrogen-13-labeled L-glutamate. J Nucl Med 20; 782–784PubMedGoogle Scholar
  23. 23.
    Reiman RE, Huvos AG, Benua RS, Rosen G, Gelbard AS, Laughlin JS (1981) Quotient imaging of N-13 L-glutamate in osteogenic sarcoma: correlation with tumor viability. Cancer 48; 1976–1981PubMedCrossRefGoogle Scholar
  24. 24.
    Reiman RE, Rosen G, Gelbard AS, Benno RS, Laughlin JS (1982) Imaging of primary Ewing sarcoma with N-13 L-glutamate. Radiol 142; 495–500Google Scholar
  25. 25.
    Sordillo PP, Reiman RE, Gelbard AS, Benua RS, Magill GB, Laughlin JS (1982) Scanning with N-13 glutamate: assessment of the response to chemotherapy of a patient with embryonal rhabdomyosarcoma. Am.’ Clin Oncol (CTf) 5; 285–289Google Scholar
  26. 26.
    Reiman RE, Benua RS, Gelbard AS, Allen JC, Vomero JJ, Laughlin JS (1982) Imaging of brain tumors following administration of DEN-13] glutamate 1 Nucl Med 23; 682–687Google Scholar
  27. 27.
    Yeh SDI, Henna RS, Grando R, Graham MC (1980) Fluorine-18 positron emission tomography of bone lesions. J Nucl Med 21 (6); P56Google Scholar
  28. 28.
    Yeh SDJ, Myers WG, Grando R, Reiman RE and Benua RS (1982) Carbon-11 dioxide imaging in bone tumors. In: Raynaud C (ed) Nuclear Medicine and Biology. Pergamon Press, pp 1992–1995Google Scholar
  29. 29.
    Gelbard AS, Benua RS, Reiman RE, McDonald JM, VomeroJJ, Laughlin JS (1980) Imaging of the human heart after administration of L-(N-13)-glutamate. J Nucl Med 21; 988–991Google Scholar
  30. 30.
    Moses J, BorerJS, Gelbard A, Reiman R, Devereaux R, Graham M, Lamonte C (1982) Myocardial glutamate metabolism in man: relation of uptake to left ventricular function in aortic regurgitation. Clin Res 30; 208AGoogle Scholar
  31. 31.
    Clarke LP, Laughlin JS, Mayer K (1972) Quantitative organ uptake measurement. Radial 102; 375–382Google Scholar
  32. 32.
    Clarke LP, Maugham EZ, Laughlin JS, Knapper WH, Mayer K (1976) Calibration methods for measuring splenic sequestration by extemal scanning. Med Phys 3; 324–327PubMedCrossRefGoogle Scholar
  33. 33.
    Brownell GL, Durham CA (1974) Recent developments in positron scintigraphy. In: Hine GJ, Sorenson JA (eds) Instrumentation in nuclear medicine. New York. Academic Press, pp 135–159Google Scholar
  34. 34.
    Canal LR (1978) Design and performance characteristics of a production model positron imaging system. IEEE Trans Nucl Sci NS-25 (1); 606–614Google Scholar
  35. 35.
    French RJ, McReady VR (1967) The use of F-18 for bone scanning. Br 1 Radiol 40: 655–661CrossRefGoogle Scholar
  36. 36.
    Laughlin IS, Benua RS, Gelbard AS, Reiman RE et al (1981) Report on compounds labeled with N-13 or C-11 used in cancer metabolic studies with quantitative two-dimensional scanning and PET tomography. In: Medical radionuclide imaging (vol II ). Vienna. IAEA, p 249Google Scholar
  37. 37.
    Rosenspire KC, Gelbard AS, Cooper AIL, Schmid FA, Roberts J, YoungCW (1982) Uptake and metabolic fate of N-13 ammonia and glutamine in glutaminase sensitive and resistant marine tumors. J Nod Med 23 (5); p 37–38Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1984

Authors and Affiliations

There are no affiliations available

Personalised recommendations